PR98321

GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP(TM) and future new products.

SINGAPORE, Oct. 17, 2022 /PRNewswire=KYODO JBN/ --

GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced

a strategic collaboration with Hibiocy Co. Ltd., a private corporation based in

Bangkok, Thailand, to accelerate a respiratory-care medical device,

COVITRAP(TM) which contains human antibody for Covid-19 inhibiting project.

COVITRAP(TM) is a nasal spray which is capable of preventing the Covid-19 virus

from attaching to the internal surfaces of the nasal cavity, thus reduces the

viral load in the cavity. COVITRAP(TM) was successfully approved by Thai FDA

and was officially launched in Thailand market. Hibiocy is working to launch

the COVITRAP(TM) nasal spray device on other countries as well. GenScript

ProBio will be the exclusive service partner for the upcoming commercial

manufacturing.

Both parties are committed to the discovery of human antibody that can bind to

the Covid-19 virus and effectively inhibit infections, which is part of the key

element in the COVITRAP(TM) nasal spray device. This partnership will leverage

synergies in the complementary strengths and capabilities from both research

and discovery units using their next-generation technologies to accelerate the

development of innovative and highly effective respiratory-care solutions

against Covid-19 virus, from target identification to commercial manufacturing.

The COVITRAP(TM) device will bring benefit to the public by offering extra

protection against the Covid-19 virus. Aside from the COVITRAP(TM) project,

both parties are dedicated to set off a future long term collaboration for new

product and manufacturing in near future.

GenScript ProBio, a global one-stop CDMO from GenScript Group specializes in

single B cell, phage display, hybridoma, fully human and bispecific antibody

technologies, commits to facilitate biological drugs from discovery to

development and commercial use. Under this agreement, GenScript ProBio will

continuously be the exclusive service partner from clinical material

manufacturing to commercial manufacturing and provide professional consultation

to Hibiocy for future new products. Top priority to access GMP service will be

granted to Hibiocy to accelerate the antibody drug development.

"This collaboration with GenScript in this ground-breaking discovery behind the

development of innovative respiratory-care medical device with human antibody

for inhibiting Covid-19 is critical given the growing concern of Covid-19

impacting daily life as well as unknown long Covid-19 impacts and more

uncertain conditions from infections. We believe this discovery and

collaboration with GenScript will bring global innovative solution with a

bright opportunity for us to protect and save more lives from either getting

infected or reinfected from new variances of Covid-19. In the end, this life

changing solution will bring back a normal life for everyone."  Ms. Worrawan

Chaikamnerd, CEO at Hibiocy and KISS said.

GenScript ProBio – Biologics CDMO

"At GenScript, we are resolute in our commitment to advancing human health as

part of our mission to save and improve lives," said Mr. Johnson Wang,

President of GenScript Asia Pacific. "We believe the Covid-19 nasal spray

device represents a promising approach to combating the novel coronavirus

pandemic and will bring benefit to the public. This collaboration with Hibiocy

brings together two companies dedicated to the fight against Covid-19 to

utilize our joint capabilities in complementary and synergistic ways to address

this difficult global health challenge."

GenScript ProBio is the subsidiary of GenScript Biotech Corporation,

proactively providing end-to-end CDMO service from drug discovery to

commercialization with proactive strategies, professional solutions and

efficient processes in cell and gene therapy (CGT), vaccine, biologics

discovery and antibody protein drug to accelerate drug development for

customers. GenScript ProBio has established companies in the United States, the

Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to

serve global customers, and supported customers in the United States, Europe,

Asia Pacific and other regions to obtain more than 30 IND approvals.

GenScript ProBio's total cell and gene therapy solution covers CMC of plasmid

and virus for IND filing as well as clinical manufacturing and commercial

manufacturing. GenScript ProBio's innovative solutions for biologics discovery

and development include therapeutic antibody discovery, antibody engineering

and antibody characterization. In biologics development service, GenScript

ProBio has built a DNA to GMP material platform, including stable cell line

development, host cell license, process development, analytical development to

clinical manufacturing, and offer fed-batch and perfusion process to meet the

growing needs for antibody and protein drugs. GenScript ProBio has established

GMP capacity which meets FDA, EMA and NMPA regulatory requirements.

Toward the mission of "Innovation through Collaboration", GenScript ProBio is

committed to helping customers shorten the timeline for the development of

biological drugs from discovery to commercialization, significantly lowering

R&D costs and building a healthier future.

About Hibiocy Co. Ltd

Hibiocy Co. Ltd is a private corporation based in Bangkok, Thailand, the

affiliate of Rojukiss International Public Company Limited (KISS) – the leading

Thai-based Beauty & Health company. Hibiocy is established to lead the

sourcing, procuring and manufacturing the Anti-COVID nasal spray, trade-name

"Vaill COVITRAP", and future new products in healthcare business.

Hibiocy is a newly established organization in Thailand that collaboratively

works with key leading partners including Health Systems Research Institute

(HSRI), the Faculty of Medicine at Chulalongkorn University, the Faculty of

Pharmacy at Silpakorn University and the Government Pharmaceutical Organization

(GPO) in jointly developed an anti-COVID nasal spray, a ground breaking

innovation that fully approved by Thai FDA and commercialized since early

October this year.  

SOURCE: Genscript

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=431691

   Caption: Ms. Worrawan Chaikamnerd, CEO at Hibiocy and KISS (left) and Mr. Johnson Wang,

President of GenScript Asia Pacific (right)